SEOUL, South Korea--(BUSINESS WIRE)--A clinical study on safety found that multiple intravenous administrations of cultured human autologous adipose-derived stem cells which were cultured by Biostar ...

Objective and design: The use of proton pump inhibitors in acid-related diseases such as peptic ulcer or erosive reflux oesophagitis is well established. The aim of the current nationwide, multicentre ...

Please provide your email address to receive an email when new articles are posted on . A 500 mg intramuscular injection of sotrovimab was noninferior to an IV infusion of the investigational ...

Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.

Please provide your email address to receive an email when new articles are posted on . DENVER — Subcutaneous administration of ocrelizumab showed similar safety and efficacy profiles to IV ...

Medically reviewed by Marla Anderson, MD Key Takeaways IV therapy delivers cancer medicine directly into a vein and often ...

The benefit of reduced intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) as salvage treatment for relapsing multiple myeloma (MM) Bortezomib (Bz) is a novel proteasome ...

Rapid 30-minute isatuximab infusions improve patient experiences and reduce healthcare system burdens without compromising safety. FDA-approved isatuximab with VRd shows a 40% risk reduction in ...

It Takes a Village! Navigating the Challenges and Opportunities in Immune-Related Adverse Event Management More broadly than this study, several contextual factors need to be considered before simply ...

BETHLEHEM, Pa., Sept. 21, 2021 /PRNewswire/ — B. Braun Medical Inc. (B. Braun), a leader in infusion therapy and pain management, announced today the launch of its new CARESAFETM IV Administration ...

The phase 3 IRAKLIA trial showed isatuximab's OBDS matches IV efficacy and pharmacokinetics, with fewer injection-site reactions. Subcutaneous isatuximab demonstrated a 71.1% objective response rate, ...